Contact CFFC

Feb

Clinical Trial Alerts – February 2021

Cystic Fibrosis Foundation issued the following clinical trial alerts in February.

February 5, 2021

Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis

Status: Completed with Results

Description: This study evaluated the effectiveness of the inhaled drug vancomycin hydrochloride inhalation powder (AeroVanc) in adults and children 6 years and older with CF and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

Age: 6 Years to 21 Years

Mutation: No Mutation Requirement

Fev1% Predicted: 30 to 90%

Number of Visits: 13

Length of Participation: 12 months

ClincalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT03181932

February 8, 2021

STOP-PEDS Pilot: Study to evaluate treatment of pulmonary exacerbations in children 6-18 years old with CF

Status: Enrolling

Description: This study will evaluate children 6 to 18 years old with CF to determine the acceptability and feasibility of a larger trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation treatment.

Age: 6 Years to 18 Years

Mutation: No Mutation Requirement

Fev1% Predicted: 50% or greater

Number of Visits: 3

Length of Participation: 18 months

ClincalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04608019


Comments are closed.